Replies to post #30766 on Marker Therapeutics Inc (MRKR)

[attilathehunt]

Is this about Marker?

Several years ago (more like 5 years) I remember reading an abstract about a trial and it was glowing. I figured out who had the drug and bought several thousand shares at around $2....Needless to say, the company did issued a PR about a week later and the stock jumped to the teens and a couple of months later it was sold in the 30's. I want to say it was CPXX.


Maybe something similar will happen here and thus may explain the recent activity.

[microcapbiotech]

This has to be Marker. All the authors are from Baylor.

Spyridoula Vasileiou, PhD1; Premal D. Lulla, MD1; Ifigeneia Tzannou, MD1; Ayumi Watanabe, BSc1; Manik Kuvalekar, MSc1; Wendy L. Callejas, BSc1; Mrinalini Bilgi, BSc1; Tao Wang, PhD1; Mengfen J. Wu, BSc1; Rammurti Kamble, MD1; Carlos A. Ramos, MD1; Rayne H. Rouce, MD1; Zihua Zeng, MD1; Adrian P. Gee, PhD1; Bambi J. Grilley, RPh1; Juan F. Vera, MD1; Catherine M. Bollard, MD1; Malcolm K. Brenner, MD, PhD1; Helen E. Heslop, MD1; Cliona M. Rooney, PhD1; Ann M. Leen, PhD1; and George Carrum, MD1
1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX

I see Juan Vera, Helen Heslop, Ann Leen.
The 5 TAA targets are what Marker is using.

[rockchalk2]

Great find! That is our TACTAL trial. We just hit our primary completion last month. I can't find a date on the article, but I would assume it pertains to that. If that's the case, I wouldn't be surprised if they submit it for ASCO. But of course, I would love a PR asap. Lol